File(s) not publicly available
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
journal contribution
posted on 2023-02-14, 23:30 authored by P Ghia, A Pluta, M Wach, D Lysak, M Šimkovič, I Kriachok, Á Illés, J De La Serna, S Dolan, P Campbell, G Musuraca, A Jacob, EJ Avery, JH Lee, G Usenko, MH Wang, T Yu, W JurczakAcalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results
History
Journal
HemaSphereVolume
6Pagination
E801-Location
United StatesPublisher DOI
ISSN
2572-9241eISSN
2572-9241Language
enIssue
12Publisher
Ovid Technologies (Wolters Kluwer Health)Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC